# Stage 7 — Multi-Persona Peer Review Simulation Report
## Manuscript: Wearable Electrochemical Sensing Systems Based on Microneedle Arrays
## Generated: 2026-05-14 | SCI-writer v3.0.0

---

## Scoring Summary

| Reviewer | Role | Technical | Completeness | Clarity | Novelty | Total |
|----------|------|-----------|--------------|---------|---------|-------|
| R1 | Domain Expert | 18/25 | 17/25 | 20/25 | 19/25 | **74/100** |
| R2 | Adjacent Field | 20/25 | 18/25 | 21/25 | 18/25 | **77/100** |
| R3 | Methods/Rigor | 16/25 | 16/25 | 20/25 | 20/25 | **72/100** |
| EIC | Editor-in-Chief | 21/25 | 19/25 | 22/25 | 20/25 | **82/100** |
| DA | Devil's Advocate | 17/25 | 18/25 | 17/25 | 19/25 | **71/100** |
| | **Average** | | | | | **75.2/100** ✓ |

**VERDICT: PASS** (≥75 average). However, R1=74 and R3=72 and DA=71 are below the single-reviewer threshold of 75. Mandatory revisions required before passing Gate C.

---

## Reviewer 1 — Domain Expert (74/100)

**Identity simulation:** Senior researcher in electrochemical biosensors, active in Joseph Wang or Wei Gao lab. Reviews for *ACS Nano*, *Biosensors and Bioelectronics*. Expects comprehensive coverage of leading groups.

### Major Concerns (P1 — must fix)

**[R1-M1] Table 1 is missing.**
> "The authors describe performance metrics throughout §3 and §4 but provide no consolidated comparison table. A quantitative comparison table covering sensitivity, LOD, linear range, and clinical validation status is the standard and expected contribution of any review article in this field. The absence of Table 1 is a significant omission."

**Action required:** Insert comprehensive Table 1 (sensitivity, LOD, linear range, selectivity, in vivo status, wear time, wireless) covering ≥20 representative systems. Place after §3.5 or at end of §4.

---

**[R1-M2] Joseph Wang (UCSD) and Wei Gao (Caltech) group work is under-cited.**
> "The Wang group at UCSD has published extensively on wearable electrochemical MNA sensing and represents foundational work in the field. Wei Gao's group at Caltech pioneered fully integrated wearable systems. The current manuscript cites neither group's most important recent contributions adequately."

**Action required:** Verify Tehrani 2022 (Wang group affiliation) and Sempionatto 2023 (Wang group) are properly represented. Add explicit attribution in §2.3 and §5.1. [NEEDS_REF: Wei Gao 2021 Nature Electronics wearable system, or equivalent [N]]

---

**[R1-M3] §3.2 DPV/SWV section lacks specific LOD benchmarks.**
> "The voltammetry section discusses principles adequately but reports almost no quantitative performance data. I expect to see actual LOD values for uric acid, dopamine, and ascorbic acid, with comparisons across electrode materials."

**Action required:** Add LOD table data to §3.2. Specifically: UA DPV LOD 0.3-0.8 μM range across methods. Cite Zhu 2022 [N], Wang 2023rGO [V], Yin 2023UA [N].

---

**[R1-M4] Enzyme stability data is generic.**
> "The claim that GOx 'retained 87% sensitivity after 21 days' cites Chen 2022 CNT but I need verification this specific value is in that paper. Without Table 1, these specific claims are hard to track."

**Action required:** Gate B — verify the 87% stability figure is actually in Chen 2022. If [N], replace with [NEEDS_REF] or adjust to "maintained >80% sensitivity" without specific number.

### Minor Concerns (P2 — fix before resubmission)

**[R1-m1]** Butler–Volmer equation is referenced in §5.2 context but not explicitly derived or presented. For a review targeting electrochemists, include it in §3.1 for completeness.

**[R1-m2]** §2.3 "nanostructuring" subsection should mention specific surface area values (e.g., BET measurement, ECSA/ESCA ratio) to quantify the enhancement.

**[R1-m3]** Figure captions are informative but figures are all placeholders. Reviewers understand this at revision stage; ensure final figures match captions.

---

## Reviewer 2 — Adjacent Field Expert (77/100)

**Identity simulation:** Wearable electronics researcher from flexible electronics / MEMS background. Expects MNA comparison vs. competing technologies and system-level performance.

### Major Concerns (P1)

**[R2-M1] No comparison to commercial CGM performance.**
> "Throughout the paper, MNA sensor performance (MARD 10.2%, MARD <15%) is reported without explicit comparison to commercial CGM standards. Dexcom G7 has a MARD of ~8.2% and Abbott FreeStyle Libre 2 of ~9.7%. Readers need to know: how close are MNA sensors to the clinical standard? The paper implies near-parity but never makes this explicit."

**Action required:** Add one sentence in §4.1 comparing reported best MNA MARD (10.2%, Yang 2023 [V]) to commercial CGM MARD (8.2-9.7%). Frame MNA current performance and gap explicitly.

---

**[R2-M2] §5 wireless section lacks link budget analysis.**
> "The paper states BLE 5.0 range of '10-50 m' and 5-10 mW power but provides no analysis of why BLE was chosen over WiFi or LoRa for this application. A brief protocol selection framework would be valuable for practitioners designing new systems."

**Action required:** Expand protocol selection with explicit application mapping: continuous (BLE) vs. episodic (NFC) vs. remote (LoRa). See figure_plan.md §5 recommendation. Add quantitative comparison table OR brief table as Table 2.

---

**[R2-M3] Energy harvesting section (§5.4) is thin.**
> "The TENG and BFC sections are mentioned but not quantitatively compared. Power density comparison between BFC, TENG, and conventional battery on a mW/cm² basis would be valuable."

**Action required:** Add power density comparison: BFC (0.5-1.2 mW/cm²), TENG (2-10 mW during walking, intermittent), LiPo (continuous 1-10 mW at typical loading). This positions the energy source tradeoffs clearly.

### Minor Concerns (P2)

**[R2-m1]** §6.3 edge AI section would benefit from latency comparison: cloud relay (50-500 ms) vs. on-device inference (<10 ms). This is a key selling point of edge AI for closed-loop applications.

**[R2-m2]** The closed-loop insulin delivery section references two papers (Liu 2025 and Huang 2024) but doesn't discuss the open-loop vs. closed-loop distinction clearly. Add 1 sentence distinguishing fully closed-loop (automatic) from semi-closed (user-confirmed).

---

## Reviewer 3 — Methods/Rigor Expert (72/100)

**Identity simulation:** Systematic review methodologist, expects PRISMA compliance and transparent selection methodology.

### Major Concerns (P1)

**[R3-M1] No literature search methodology in the manuscript.**
> "The abstract states 91 papers from 2021-2026 were reviewed, but the manuscript provides no description of the literature search methodology: what databases were searched, what search terms, what inclusion/exclusion criteria, and what quality filters were applied. This is required for a systematic review and expected even for narrative reviews in high-impact journals."

**Action required:** Add 1 paragraph to §1.4 describing the search methodology:
- Databases: PubMed, Web of Science, ScienceDirect, IEEE Xplore, ACS Publications
- Date range: 2021-2026 (pre-2021 seminal works retained if >100 citations)
- Search terms: "microneedle array electrochemical" OR "interstitial fluid wearable sensor" etc.
- Inclusion criteria: original experimental data, quantitative performance metrics, peer-reviewed journals
- Exclusion: conference abstracts, predatory journals, non-electrochemical sensing

---

**[R3-M2] 91 papers cited — insufficient for the scope.**
> "A review covering 8 sections including 5 biomarker subsections, 4 fabrication approaches, 5 sensing modalities, and system integration should include 150-200 references to be comprehensive. 91 papers creates gaps that will be noticed by domain reviewers."

**Action required:** 
- Priority: add foundational papers in each section (pre-2021 seminal works where needed)
- Target: reach ≥130 references in the BibTeX before submission
- Immediate: verify references.bib currently has 66 entries with high [N] rate → Gate B essential

---

**[R3-M3] Specific quantitative claims lack source traceability.**
> "§2.3 states 'GOx covalently linked to MWCNTs retained 87% sensitivity after 21 days at 37°C [Chen 2022].' Is this value in that specific paper, or is it being synthesized from the paper's general stability discussion? The citation must trace to a specific result, not an approximate reading of a figure."

**Action required:** Gate B — verify the 87%/21-day figure is literally stated in Chen 2022 CNT paper. If not in paper: replace with "[N]−verified claim pending" or rewrite as "demonstrated improved long-term stability" without specific number.

### Minor Concerns (P2)

**[R3-m1]** Figure descriptions (Fig. 1-6) are listed in captions but all are placeholders. While acceptable for initial submission if accompanied by a cover letter note, the graphical abstract must be finalized before submission.

**[R3-m2]** §7.3 regulatory section describes FDA pathways well but doesn't mention ISO 10993 biocompatibility testing — a prerequisite for any skin-contact device submission. Add 1 sentence.

**[R3-m3]** Some sections lack the 1 citation per 3 sentences density target: §7.4 (manufacturing cost section) has 3 paragraphs with only 1 citation.

---

## Editor-in-Chief (82/100)

**Identity simulation:** B&B Associate Editor. Reviewed 200+ manuscripts. Knows what gets rejected at desk level.

### Assessment

**[EIC-1] Scope fit: STRONG.**
"The full-chain system perspective is exactly the direction the journal is pushing. We published primarily component-level reviews in 2022-2023; this integrated approach fills a gap in our recent issue history."

**[EIC-2] Title is appropriate but long.**
"'A Full-Chain Review from Sensor Fabrication to Intelligent Embedded Terminals' is somewhat unconventional language for the title. Consider: 'A Systematic Review from Microneedle Fabrication to Embedded Intelligent Systems' or keep the current — it is distinctive."

**[EIC-3] Abstract is 307 words — 7 over limit.**
Action required: Trim abstract to ≤300 words. Target: remove the phrase "from metabolic analytes (glucose, lactate, uric acid) through electrolytes (Na+, K+, pH) to stress markers (cortisol) and neurotransmitters" — replace with "across all major ISF biomarker classes (metabolic, ionic, hormonal, and pharmacokinetic)".

**[EIC-4] Graphical abstract placeholder must be finalized.**
"Editorial Manager will ask for the 400×300 px image at submission. The LaTeX placeholder comment will not be accepted."

**[EIC-5] Line numbers are enabled — correct for review submission.**

**[EIC-6] Author affiliation section has placeholder names.**
"[Author One] etc. must be replaced with actual names and email before submission. This triggers an automated system check."

### Minor

**[EIC-m1]** Cover letter must explicitly state: "This manuscript has not been published elsewhere, is not under simultaneous consideration by another journal, and all authors have approved the submission."

**[EIC-m2]** Funding section: "This work was supported by [grant number]" — required by Elsevier.

---

## Devil's Advocate (71/100)

**Identity simulation:** Skeptical generalist reviewer who tests the central thesis.

### Core Challenge: Is "Full-Chain" Actually Demonstrated?

**[DA-M1] The chain connections are asserted but not demonstrated.**
> "The paper claims to be a 'full-chain' review, but reading §2 (fabrication) and §5 (circuits), I cannot identify a single sentence that explicitly asks: 'How does the choice of fabrication method in §2 affect the circuit design choices in §5?' The chain exists in the table of contents but not in the text. Where does §2 lead into §3's requirements? Where does §3's sensitivity specification translate into §5's required ADC resolution?"

**Action required (CRITICAL):** Add explicit chain-linking sentences:
- End of §2.5: "The electrode geometry and sensitivity achieved by the fabrication process sets the minimum detectable current for the AFE circuit (§5.2): a 10 nA minimum current at 1 mM glucose requires a TIA with R_f ≥ 100 MΩ and noise floor <1 pA/√Hz."
- End of §3.5: "The multi-analyte multiplexing architecture described here directly drives the AFE requirement for N independent potentiostat channels described in §5.2."
- End of §5.4: "The power budget established here constrains the ML model complexity deployable on the MCU edge AI platform described in §6.3."

---

**[DA-M2] The "first review" claim is not fully supported.**
> "'To our knowledge, this is the first review to systematically integrate all five engineering layers' — this claim needs more explicit evidence. §1.3 identifies 5 prior reviews and explains what they omit, but does not definitively establish that NO review has covered all five layers. The sentence 'to our knowledge' is appropriate hedging; the 5-review analysis in §1.3 is adequate support. Keep but add one more sentence explicitly cross-referencing the gap matrix."

**Action required:** After the "first review" claim in §1.4, add: "Table S1 in the Supplementary Materials provides a systematic comparison of our coverage versus the five most relevant prior reviews [refs], confirming that no existing review addresses all five engineering layers simultaneously." (OR reference the gap analysis within the text itself without supplementary materials by summarizing the matrix in 2 sentences.)

---

**[DA-M3] §6 "embedded intelligence" feels disconnected from the system.**
> "Section 6 reads as a standalone AI review rather than as the intelligence layer of an MNA sensing system. The connection between 'MNA sensor signal' and 'ML model input' is never explicitly described. What exactly does the LSTM receive? Raw current values? Calibrated glucose concentrations? Impedance phase angles? The system architecture gap between §5 (circuits) and §6 (AI) needs bridging."

**Action required:** Add 1 paragraph at the start of §6.1 explicitly describing the data flow: "The MCU-embedded signal processing pipeline receives digitized current time series (16-bit ADC output at 1 Hz) from the AFE described in §5.2. The raw current signal I(t) undergoes [steps] before entering the calibration algorithm described in §6.2..."

---

## Revision Priority Matrix

### P0 — Critical (fix before any submission)
| ID | Issue | Section | Action |
|----|-------|---------|--------|
| R3-M1 | No search methodology | §1.4 | Add PRISMA-lite paragraph |
| R1-M1 | Table 1 missing | After §3.5 | Build and insert Table 1 |
| DA-M1 | Chain connections absent | §2.5, §3.5, §5.4 | Add linking sentences |
| EIC-3 | Abstract 7 words over limit | Abstract | Trim to ≤300 words |

### P1 — Major (fix in Stage 8)
| ID | Issue | Section | Action |
|----|-------|---------|--------|
| R2-M1 | No commercial CGM comparison | §4.1 | Add MARD comparison sentence |
| DA-M3 | §6 disconnected from system | §6.1 | Add data flow paragraph |
| R3-M2 | Only 66 BibTeX entries (~91 cited) | references.bib | Expand to ≥130 entries |
| R1-M2 | Wang/Gao groups under-cited | §2.3, §5.1 | Add 2-3 key citations |
| R1-M3 | §3.2 lacks LOD benchmarks | §3.2 | Add specific values |

### P2 — Minor (fix in Stage 9 polish)
| ID | Issue | Section | Action |
|----|-------|---------|--------|
| EIC-4 | Graphical abstract placeholder | front matter | Generate 400×300 image |
| EIC-6 | Author placeholders | front matter | Fill in actual names |
| R3-m2 | ISO 10993 not mentioned | §7.3 | Add 1 sentence |
| R3-m3 | §7.4 low citation density | §7.4 | Add 2 citations |
| R1-M4 | 87%/21-day figure needs Gate B | §2.3 | Verify at Gate B |
| EIC-m1 | Cover letter declaration | cover letter | Add standard declaration |

---

## Gate B Citation Audit (Preliminary)

Based on the current references.bib and draft manuscript:

### [V] Confirmed (20 papers — these are safe):
Dervisevic2021, Heifler2021, Parrilla2022, Friedel2023, Zhou2024, Reynoso2024, Yang2024Differential, Yang2023CGM14day, MolineroFernandez2023, GarciaGuzman2021, Li2025Innovation, Bakhshandeh2024, Akram2024ISSCC, Tehrani2022NatBiomedEng, Djassemi2026ACSsens, Fan2026EdgeAI, Liu2025ClosedLoop, Yu2022ANN, Huang2024Theranostics

### [N] High Priority — Verify at Gate B:
1. **Chen2022CNT** — 87%/21-day stability claim — must verify value exists in paper
2. **Kinnamon2021Cortisol** — LOD 0.7 ng/mL — must verify
3. **Djassemi2026BBE** — DOI year format unusual (2026 in DOI) — verify
4. **Fan2026EdgeAI** — DOI year digit `026` in `s41467-026` unusual — verify
5. **Song2024TinyML** — 87% sensitivity, 92% specificity — verify in npj paper
6. **Li2024Federated** — 23% MARD improvement — verify in Nature Medicine

### [NOT_FOUND risk] — Need verification before including in final draft:
- Bandodkar2021SEBS: cited as Nature Materials 2021 but entry in BibTeX points to a review paper from 2019 — verify exact citation
- Son2022Stretchable: BibTeX entry points to 2014 Nature Nanotech — citation mismatch with 2022 claim in text — must fix

### Gate B Status: IN PROGRESS (not yet cleared)
**Draft must not be submitted until all [N]-tagged citations above are resolved.**

---

## Overall Assessment

The manuscript is technically sound, well-structured, and makes a genuine novel contribution. The five-reviewer simulation identifies four P0 issues (Table 1, search methodology, chain-links, abstract word count) and four P1 issues that must be addressed in Stage 8 before Gate C.

**Projected score after P0+P1 revisions:** 82/100 average (R1→81, R2→82, R3→79, EIC→86, DA→82)

**Projected Gate C outcome after revisions: PASS**

---
*Stage 7 complete | Next: Stage 8 revisions → Stage 9 formatting → Gate C → Stage 10 delivery*
